公开(公告)号：US09943580B2

公开(公告)日：2018-04-17

申请号：US15023653

申请日：2014-09-11

Applicant: STC.UNM ,  LEIDOS, INC

Inventor： David S. Peabody ,  Bryce Chackerian ,  James Pannucci ,  Gabriel M. Gutierrez ,  Amy Rene Noe ,  Scott Budd Winram ,  Steve Chienwen Huang

IPC: A61K39/39 ,  A61K39/015 ,  C12N7/00 ,  C12N15/10 ,  A61K39/00 ,  A61K35/76

CPC classification number: A61K39/015 ,  A61K35/76 ,  A61K39/39 ,  A61K2039/5256 ,  A61K2039/5258 ,  A61K2039/55566 ,  C07K2319/40 ,  C12N7/00 ,  C12N15/1037 ,  C12N2795/18122 ,  C12N2795/18123 ,  C12N2795/18134 ,  Y02A50/412

Abstract: Embodiments are directed to malaria vaccines comprising a bacteriophage VLP displaying a heterologous peptide identified by affinity selection as an anti-malaria mimotope.

公开(公告)号：US11987646B2

公开(公告)日：2024-05-21

申请号：US17497069

申请日：2021-10-08

Applicant: Leidos, Inc.

Inventor： Gabriel M. Gutierrez ,  James Pannucci ,  Michael Ryan Weil ,  Timothy W. Phares ,  Vinayaka Kotraiah ,  Cecille D. Browne ,  Peter J. Buontempo

IPC: A61P35/00 ,  A61K38/10 ,  A61K45/06 ,  C07K7/08

CPC classification number: C07K7/08 ,  A61K38/10 ,  A61K45/06 ,  A61P35/00

Abstract: This disclosure provides peptides which can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer; treating infectious diseases; enhancing a response to vaccination; treating sepsis; and promoting hair re-pigmentation or lightening of pigmented skin lesions.

公开(公告)号：US11033622B2

公开(公告)日：2021-06-15

申请号：US15989750

申请日：2018-05-25

Applicant: Leidos, Inc.

Inventor： Gabriel M. Gutierrez ,  Vinayaka Kotraiah ,  Timothy W. Phares ,  James Pannucci

IPC: A61K39/395 ,  C12N15/00 ,  C07K7/06 ,  C07K14/705 ,  C07K16/28 ,  C07K7/08 ,  A61K39/39 ,  A61P35/00 ,  A61K31/7105 ,  A61K35/17 ,  A61K39/00 ,  A61K45/06 ,  A61K38/00 ,  A61K35/76 ,  A61P33/06 ,  A61P31/04

Abstract: This disclosure provides peptides which have a strong affinity for the checkpoint receptor “programmed death 1” (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 as well as the interaction of CTLA4 with CD86 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer; treating infectious diseases; enhancing a response to vaccination; treating sepsis; and promoting hair re-pigmentation or lightening of pigmented skin lesions.

公开(公告)号：US10799555B2

公开(公告)日：2020-10-13

申请号：US15906481

申请日：2018-02-27

Applicant: Leidos, Inc.

Inventor： Gabriel M. Gutierrez ,  Vinayaka Kotraiah ,  James Pannucci ,  Ramses Ayala

IPC: A61K38/10 ,  A61K39/015 ,  A61K38/16 ,  A61K39/00 ,  A61K35/17 ,  A61K38/19 ,  A61P33/06 ,  A61P31/20 ,  A61P37/04 ,  A61P35/04 ,  A61K45/06 ,  C07K7/08 ,  C07K14/00 ,  A61K39/39 ,  A61K48/00

Abstract: This disclosure provides peptides which have a strong affinity for the checkpoint receptor “programmed death 1” (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer; treating infectious diseases; enhancing a response to vaccination; treating sepsis; and promoting hair re-pigmentation or lightening of pigmented skin lesions.

公开(公告)号：US10098950B2

公开(公告)日：2018-10-16

申请号：US15705333

申请日：2017-09-15

Applicant: Leidos, Inc.

Inventor： Gabriel M. Gutierrez ,  Vinayaka Kotraiah ,  James Pannucci ,  Ramses Ayala

IPC: A61K6/00 ,  A61K39/00 ,  A61K39/002 ,  A61K39/015 ,  A61K39/395 ,  A61K45/00 ,  A61K45/06 ,  C07K1/00 ,  C07K16/00 ,  C07K16/18 ,  C07K16/20 ,  A61K39/39 ,  A61K38/16 ,  A61K38/10 ,  C07K7/08

Abstract: This disclosure provides peptides which have a strong affinity for the checkpoint receptor “programmed death 1” (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer, treating infectious diseases, enhancing a response to vaccination, and treating sepsis.

公开(公告)号：US20210275669A1

公开(公告)日：2021-09-09

申请号：US17317985

申请日：2021-05-12

Applicant: Leidos, Inc.

Inventor： Gabriel M. Gutierrez ,  Vinayaka Kotraiah ,  Timothy W. Phares ,  James Pannucci

IPC: A61K39/395 ,  C12N15/00 ,  C07K7/06 ,  C07K14/705 ,  C07K16/28 ,  C07K7/08 ,  A61K39/39 ,  A61P35/00 ,  A61K31/7105 ,  A61K35/17 ,  A61K39/00 ,  A61K45/06

Abstract: This disclosure provides peptides which have a strong affinity for the checkpoint receptor “programmed death 1” (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 as well as the interaction of CTLA4 with CD86 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer; treating infectious diseases; enhancing a response to vaccination; treating sepsis; and promoting hair re-pigmentation or lightening of pigmented skin lesions.

公开(公告)号：US20200369766A1

公开(公告)日：2020-11-26

申请号：US16879884

申请日：2020-05-21

Applicant: Leidos, Inc.

Inventor： Gabriel M. Gutierrez ,  Vinayaka Kotraiah ,  Timothy W. Phares ,  James Pannucci ,  Marc Mansour

IPC: C07K16/28 ,  C12N15/11 ,  A61K39/395 ,  A61K45/06

Abstract: This disclosure provides peptides which bind to LAG3 and can be used to block the interaction of LAG 3 with other molecules such as MHC-II, FGL1, and α-synuclein. These peptides can be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer, or inhibiting the progression of a synucleinopathy, inhibiting the progression of sepsis, inhibiting the progression of an infectious disease, and enhancing a response to a vaccine.

公开(公告)号：US20180339044A1

公开(公告)日：2018-11-29

申请号：US15989750

申请日：2018-05-25

Applicant: Leidos, Inc.

Inventor： Gabriel M. Gutierrez ,  Vinayaka Kotraiah ,  Timothy W. Phares ,  James Pannucci

IPC: A61K39/395 ,  A61K45/06 ,  A61P35/00 ,  A61K35/17 ,  A61K39/00 ,  A61K31/7105

Abstract: This disclosure provides peptides which have a strong affinity for the checkpoint receptor “programmed death 1” (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 as well as the interaction of CTLA4 with CD86 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer; treating infectious diseases; enhancing a response to vaccination; treating sepsis; and promoting hair re-pigmentation or lightening of pigmented skin lesions.

公开(公告)号：US20180200328A1

公开(公告)日：2018-07-19

申请号：US15906481

申请日：2018-02-27

Applicant: Leidos, Inc.

Inventor： Gabriel M. Gutierrez ,  Vinayaka Kotraiah ,  James Pannucci ,  Ramses Ayala

IPC: A61K38/10 ,  A61K39/39 ,  A61K39/015 ,  A61K38/16 ,  A61K39/00 ,  A61K35/17 ,  A61K38/19 ,  A61P33/06 ,  A61P31/20 ,  A61P37/04 ,  A61P35/04 ,  A61K45/06 ,  C07K7/08 ,  C07K14/00

CPC classification number: A61K38/10 ,  A01K2227/105 ,  A01K2267/0331 ,  A01K2267/0337 ,  A61K35/17 ,  A61K38/16 ,  A61K38/19 ,  A61K39/0011 ,  A61K39/015 ,  A61K39/39 ,  A61K45/06 ,  A61K48/00 ,  A61P31/20 ,  A61P33/06 ,  A61P35/04 ,  A61P37/04 ,  C07K7/08 ,  C07K14/00

Abstract: This disclosure provides peptides which have a strong affinity for the checkpoint receptor “programmed death 1” (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer; treating infectious diseases; enhancing a response to vaccination; treating sepsis; and promoting hair re-pigmentation or lightening of pigmented skin lesions.

公开(公告)号：US12269880B2

公开(公告)日：2025-04-08

申请号：US17854227

申请日：2022-06-30

Applicant: Leidos, Inc.

Inventor： Gabriel M. Gutierrez ,  Vinayaka Kotraiah ,  Timothy W. Phares ,  James Pannucci ,  Marc Mansour

IPC: C07K7/08 ,  A61K38/04 ,  A61K38/10 ,  A61K38/16 ,  A61K39/395 ,  A61K45/06 ,  C07K14/00 ,  C07K16/28 ,  C12N15/11

Abstract: This disclosure provides nucleic acids encoding peptides which bind to LAG3 and can be used to block the interaction of LAG 3 with other molecules such as MHC-II, FGL1, and α-synuclein. These peptides can be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer, or inhibiting the progression of a synucleinopathy, inhibiting the progression of sepsis, inhibiting the progression of an infectious disease, and enhancing a response to a vaccine.